SmithBio, a global bioprocessing solutions provider, is increasing its support to the EMEA market

SmithBio is the new name of Sysbiotech China (a.k.a. Shanghai Bio-Tech), an experienced and leading Asian bioprocessing solutions provider that most recently played an important role in the China emergency response to Covid-19 by supporting vaccine development at Sinovac and other Chinese institutes. In 2019 the company merged with Dutch company Rienk Management Services and is now supporting customers in the EMEA region from the new European headquarters in Edam, The Netherlands.

SmithBio B.V.
Standerdmolen 35
1135LP, Edam, The Netherlands

press contact: R. de Bruijn, VP
+31 6572 77791 or +86 1821 7350074
rienk@smithbio.eu

SmithBio is globally operating from 2 locations: SmithBio APAC from China and SmithBio Europe from The Netherlands.
Some details:
> 150 staff, several offices around China, customers in Asia, M-East and Europe;
> 20 years International experience;
10.000 M2 manufacturing sites;
ISO9001 certified.

Areas of expertise:
- bioprocess engineering (process optimization in research and up-scaling to pre-clinical trial and full GMP production);
- manufacturing of cell culture instruments and bioreactors for laboratories and industrial research;
- design, customized engineering and validation of GMP Industrial production equipment such as fermenters and bioreactors, automated and controlled holding and preparation vessels and CIP systems
- turn-key project support related to design, construction, GMP compliance, equipment supplier selection, and validation of GMP production facilities for vaccines, antibodies, and recombinant proteins, as well as for cell therapy laboratories.

This release was published on openPR.